Antiphospholipid antibodies arearisk factor forvenous and arterial thrombosis and mayc ontribute to the development of atherosclerosis.The aimofthis studywas to investigate whether antibodies to human β 2 -glycoprotein 1 ( β 2 GP1 ), as am odel of antiphospholipida ntibodies, modify the phenotype of atherosclerotic lesions. LDLr eceptor-deficient micew erei mmunized with human β 2 GP1 ,human serum albumin(HSA), or not immunized, andf ed ah igh-cholesterol diet for1 4w eeks. Somem ice also receivedp ravastatin. Immunization with human β 2 GP1 or HSAresultedinformation of autoantibodies recognizing murine β 2 GP1 or murine albumin, respectively. We quantified atherosclerotic lesion development andmRNAlevelsofinflammationassociatedp roteins in the thoraco-abdominal aorta as well as lesion development,cellularcomposition andcollagen contentin Keywords Antiphospholipid antibodies,atherosclerosis, β 2 -glycoprotein 1 , immunization, statins the aortic roots. Immunization with β 2 GP1 or HSAhad no effect on lesion size,but modified the expression in plaque areas of several inflammation-associatedp roteins. Expressiono fm atrix metalloproteinase-9, tissue factor, interferon-gammaa nd CD25 was highest in the thoraco-abdominal aortao f β 2 GP1 -immunized mice,lowest in non-immunizedm icea nd intermediate in HSA-immunized animals. Immunizationw ith β 2 GP1 ,b ut not HSA, resulted in al ower smooth muscle cella nd collagen content of lesions in aortic roots. Statin treatment partially reversed the effects of β 2 GP1 immunization. We conclude thati mmunizationw ith β 2 GP1 ,and to al esser extent with HSA, leads to modifications in the cellularand protein compositionofatherosclerotic plaques, whichare associatedwith amoreinflammatory phenotype.Statin treatment partially preventsthese changes.
Introduction
Atherosclerosis is an inflammatoryd iseasem odulated by genetic and environmental factors. Immune mechanisms maybeimplicated at differents tageso fa therosclerotic plaque development and progression. Autoimmuned iseases,s uch as systemic lupus erythematosus, have beena ssociatedw ith an increased risk of cardiovasculardisease (1) . The antiphospholipid syndrome is an autoimmune disease characterized by arterial or venous thromboembolism,a nd/or obstetric complications (including recurrent fetal loss) and the presenceofantiphospholipid antibodies (aPLA) (2) .Several studiessuggestedthat aPLA contribute to the development of atherothrombosis (3, 4) , and increased levels of aPLA have beendetected in young patients with severe atherosclerosis (5) . Furthermore,elevatedaPLAwas associatedwith an increased intima-mediathickness of the carotid artery (6) . Different mechanisms have beenproposed to explain the association of aPLA with atherosclerosis. The major target of aPLA, β 2 GP1, is present in human atherosclerotic plaques (7) . aPLAenhancethe uptakeofoxidized LDL by macrophages (8) . In addition, aPLA are knownt oa ctivate endothelialc ells and monocytes (9, 10) , leading to increased expression of tissue fac-tor (TF), of chemokines and of leukocyte-adhesion molecules. Such aPLA-mediatedc ella ctivation mayi nduce ap ro-inflammatorys tate thati sk nown to promote atherogenesis (11, 12) . Studies in an atherosclerosis animal model supportthe hypothesis that aPLA have ap roatherogenic effect.I ndeed, immunization of LDLr eceptor (LDLR)-deficient micew ith human β 2 GP1fed anormal diet resulted in acceleration of aortic fattystreak formation (13) . Similarly, an enhanced earlyatherosclerosis development wasobservedinapolipoprotein E(apoE)-deficient miceimmunized with human β 2 GP1and fedahigh-fatdiet. This effect wasnot associated with an increased susceptibilityof LDL to ex-vivo oxidation (14) but maybedue to an autoimmune response manifested by the generation of autoantibodiesd irected against murine β 2 GP1 ( 15) . In addition, transfero f β 2 GP1-reactive lymphocytespromoted fatty-streak formation in these mice, providing additionalevidencefor the implication of autoimmune mechanisms in atherogenesis (16) .
Statinsa re lipid-lowering drugsa nd arew idely used in the treatment of atherosclerosis. Theyexhibit pleiotropic effects including anti-inflammatorya nd immunomodulatoryp roperties (17) . In am urine aPLA-inducedt hrombosis model, treatment with fluvastatin resulted in adecreased thrombus sizeand diminished leukocyte adhesion to the vascularwall (18) .
Clinically, amajor determinant of the risk of myocardialinfarction is not the degree of stenosis, butrather the stability of the atherosclerotic plaques ( 11) . Histological studiesh avee stablishedthat vulnerable plaquesexhibit athin fibrous cap, alipidrich necrotic core, contain numerousi nflammatoryc ells and have arelativelylow number of smoothmuscle cells.Studiesin apoE-deficient mice, on aprolonged lipid-rich diet, have shown thatplaque rupture occurs in murine models of atherosclerosis, and that the rupturedplaquesdisplaymanyfeatures of unstable plaquesinhuman arteries (19) .
The aim of thiss tudy wast oi nvestigatet ow hat extent the generation of anti-β 2 GP1a ntibodies inducedb y β 2 GP1-immunizationi nfluenceda therosclerotic plaque development and plaquecomposition in LDL-deficient mice fedalong-term highfatdiet. Immunization with humanserum albumin wasusedasa control for potentialnon-specific autoimmune effects. In addition, we investigated the effect of pravastatin treatment on plaque development and composition.
Materialand methods

Animals
Twoe xperimental series were completed:o ne for analysis of atherosclerotic lesion sizeinthe abdominal aorta, and quantification and immuno-analysis of the root sections (36 mice),and one for gene-expression analysis in the abdominala orta (28 mice).T en-week-oldf emaleL DLR-deficient mice C57BL/6J were immunized subcutaneouslywith human β 2 GP1(akind gift of Dr.Alain Bosseloir,Z entech, Angleur,B elgium)o rh uman serum albumin (Galexis SA, Ecublens, Switzerland) both in RIBI™ adjuvant (Sigma, Saint Louis, MO,U SA). Tenµ go f antigenwas injected per mouseand a10-µg boost wasinjected 15 days later.Acontrol group with the same genetic background and derived fromthe same litterswas notimmunized. Tendays after the boost, micewere weighed, and blood wasobtained from the retro-orbital plexus. All the mice were fed ahigh-cholesterol diet (1.25%c holesterol, 0% cholate, product# D12108; Research Diets, NewBrunswick, NJ,USA)for 14 weeks.Halfof the immunized micereceivedpravastatin at 10 mg.kg -1 .d -1 in the drinkingwater.The mice were allowed accesstofood and water ad libitum.Attribution to the different immunization and pravastatin-treatment groups wasdone randomly.
After 14 weeks,micew ere sacrificed,blood samplestaken, and aortasp erfusedw ith 0.9%N aCl. Thet horaco-abdominal aorta wasfixed in 2% paraformaldehyde or frozeninliquid nitrogen formRNAextraction. The aortic roots were snap-frozen in optimalc utting temperature( OCT) compound( Microm, Walldorf, Germany)for cryosectioning.
Thee xperiments were performed according to institutional guidelines, and the study protocol wasapprovedbythe localveterinaryauthorities and ethics commission.
Anti-β 2 GP1 or anti-albumin antibodydetection Antibodies to β 2 GP1, human serum albumin (HSA) and murine seruma lbumin (MSA) were analysed by ELISA in sera of all mice at the beginningo ft he diet (10 days after the boost) and after sacrifice.ELISA microtiter plates (Maxisorp, Nunc, Roskilde, Denmark) were coated with human β 2 GP1( 15 µg/ml in phosphate-buffereds aline [PBS])( Hyphen Biomed,A ndresy, France),H SA or MSA (Sigma)( both 50 µg/ml in carbonate 
buffer pH 9.6).The plates were incubatedfor 2hours (h) at room temperaturewith serumsamples (1:50 dilutedinPBS).The presenceofIgG against human β 2 GP1, HSAorMSA wasdetected using horseradish peroxidase-conjugated goat anti-mouseI gG. The presenceofIgM against β 2 GP1w as analysed according to the same protocol and detected using alkaline phosphatase-conjugated goat anti-mouseIgM. Colour wasdeveloped by adding the appropriate substrate( R&D Systems, Abingdon, UK). Absorbances were measured at 450or490 nm, respectively. The presence of autoantibodies to mouse β 2 GP1w as analysedbysandwich ELISA. Theassaytook advantage of the immunologicalcross-reactivity between humanand mouse β 2 GP1 (15). ELISAm icrotiterp lates( Maxisorp, Nunc) were coated with immunopurifiedrabbit anti-human β 2 GP1(2µg/ml in carbonate buffer pH 9.6) (Hyphen Biomed).The plates were blocked for 2hwith 0.6%gelatine in PBS.The mouse serum samples (diluted 1:50 in PBScontaining 0.3% gelatine, 0.05% Tween 20) were incubatedfor 2hinthese plates. In this approachthe mouse β 2 GP1contained in the serum samples is capturedbythe coating antibodies and retains the autoantibodies directedagainst mouse β 2 GP1. The amount of mouseI gG bound to the plates was quantified using horseradish peroxidase-conjugated goat antimouseIgG.
Lipid analysis
Mouse plasma cholesterol concentrationsw ere determinedf or all the animals at the end of the experimental period as previouslydescribed (20) .
Assessmentofatheroscleroticlesiondevelopment
The extent of atherosclerosis in the thoraco-abdominalaorta and in the aortic roots wasassessedaccording to standardized methods (21). In short: the thoraco-abdominala orta waso pened longitudinally,and the lesion areasinen-facepreparations were stained with SudanIV. The percentage of surfacewith lipid depositsw as calculated by dividing the stained area by the total aorta surface. Sections of the roots were stained with SudanIV. Averagelesion area fromsix sections 50 µm distant from each other wascalculated. Theposition of the analysedsections within the roots wasstandardized for all animals. Lipid stainedareas were determinedusing MetaMorph6Software(Feldbach, Switzerland).
Immunohistochemistry of atheroscleroticlesions
Masson'strichrome staining To determine the smooth muscle and collagencontent of the fibrous cap, 5-µm cryosections of the aortic roots were fixedwith Bouin's solution and stainedwith Masson's trichrome reagent.
Immunohistochemicalanalysis
This wasdone on ice-cold acetone-fixed cryosections.After fixation the sections were washedi nP BS, blocked in blocking buffer (10% normal goat seruminPBS 0.1%Tween 20), washed in PBS and incubatedf or 90 minutes (min) with primarya ntibodies in blocking buffer.Rabbit anti-mouseMac 3(BD Pharmingen, San Diego, CA, USA)was used formacrophage quantification, rabbit anti-mousesmooth muscle myosin heavy chain (sm-MHC, BiomedicalTechnologies, Stoughton, MA,USA)for smoothm uscle cell (SMC)q uantification and rata nti mouse CD4 (BD Pharmingen) for T-cellq uantification. The sections were incubatedfor 45 min with biotinylatedgoat anti-rabbit IgG or biotinylatedrabbit anti-rat IgG, respectively (VectorLab, Burlingame, CA,USA). Thepresence of secondaryantibodies was revealed using an avidin-biotin-alkaline phosphatases ubstrate kit (Vector Lab). Slides were counterstained with hemalun (Sigma). Specificity wasc onfirmed by omitting the primary antibody. Collagen wasstainedwith 0.1%Sirius red in saturated picricacid.
Quantitative analysis of stainedareas wasperformed with the aidofMetaMorph 6Software. The areaswere normalized by dividing the area of specific immunostaining by the totalp laque area stainedwith SudanIVinthe proximate tissue slice.
RNAextraction andreverse transcription
TotalRNA wasextractedfrom frozen thoraco-abdominalaortas using TriReagent(MRC Inc, Cincinnati, OH,USA), according to the manufacturer'si nstructions. The RNAy ield and purity were assessed by absorbance measurementsat260 and 280 nm. From each sample, 1µgofRNA wasusedastemplatefor cDNA Figure1:Antibody binding in sera of mice immunized with human β 2 GP1 or human serum albumin(HSA)after a14-week dietperiod. IgGbindingtohuman or murine β 2 GP1 was detected in β 2 GP1 -immunizedmice and in control mice. IgGbindingtohuman or murine serumalbumin was determinedinHSA-immunized miceand controlmice.The results areshown separatelyfor micetreated with pravastatin or notand representmeans ±SEM. Thegroups of mice were:Control (CT) (n =12),HSA -pravastatinmice (n =12), HSA +pravastatinmice (n =15), β 2 GP1 -pravastatinmice (n =13), β 2 GP1 +pravastatinmice (n =12). synthesis using the ImPromII TM reverse transcription system (Promega, Madison, WI, USA). Negative controls were processedinparallelwithoutreversetranscriptase.
Quantitative real-time reversetranscriptase PCR assay
Relative mRNAlevelswere quantifiedbyreal-time PCR, using cDNAtemplates and an AppliedBiosystems Prism 7000instru-ment and SYBR-green ® PCR master mix reagent (AppliedBiosystems, Warrington, UK). Dataw ere analyzed using the Δ C T method and AppliedBiosystems Prism software and β -actinas the housekeeping-gene control. Theforwardand reverse primers for all PCRs are giveninTable 1.
Statisticalanalysis
Data are presented as mean ±s tandard error (SEM). Datas ets containing multiple groups were analysed by ANOVA followed by the non-paired Student t-test.D ifferences were considered statistically significant at ap-valueof<0.05.
Results
Analysis of antibody and cholesterol levels
Mice were immunized with eitherh uman β 2 GP1o rH SA.W e analysed whether micedeveloped antibodiesdirected againstthe injectedantigen (human β 2 GP1orHSA)and also whether mice developedautoantibodies to murine β 2 GP1orMSA.Results are giveninFigure1.Immunization of micewith human β 2 GP1re-sulted in the generation of anti-human β 2 GP1IgG that were detectable both 10 days after the boost injection, at the start the cholesterol-rich diet (notshown) and also at the end of the 14-week diet period (Fig. 1) . We were unable to detect anti-human β 2 GP1 IgM in anyofthe samples. In all mice immunizedwith human Ta ble2:Cholesterol levels at the endofthe dietperiod.
Group
Cholesterol afterdiet (mg/dl)
Control
±242
HSA no prava 2198 ±210
HSA +prava 1743 ±11 β 2 GP1 no prava 2288 ±178 β 2 GP1 +prava 1811 ±327
HSA, humanserum albumin. prava, pravastatin. β 2 GPI, β 2 -glycoprotein I.
Figure2:Determination of atheroscleroticlesiondevelopment on the thoraco-abdominal aorta (A)and in aortic roots (B).
A) To p: Lipid deposition in thoraco-abdominal aortas stainedwithSudan IV.Bottom:Quantificationofthe atheroscleroticplaquearea. Results are expressedinpercent of totalsurface of theaorta in thedifferent groups: Control(CT)(n=4),HSA -pravastatin(prava) mice(n=8),HSA + pravastatin mice(n=5), β 2 GP1 -pravastatinmice (n =7), β 2 GP1 + pravastatin mice(n=8).B)Lipid depositioninr oots stained withSudan IV: morphometricassessmentofthe plaque development. To p: Representativecross-sections of thedifferent groups areshown. Scale bar = 500 µm.Bottom:Quantificationofthe atheroscleroticplaques.The data representmeanvalues±SEM. Four mice pergroup,and sixsectionsper mousewereanalysed forthe quantificationinthe roots.*p<0.05, **p<0.01.
β 2 GP1, autoantibodies to murine β 2 GP1w ere detectable at the end of the 14-week diet period (Fig. 1) . All mice immunized withHSA hadhigh levels of anti-HSA IgG antibodiesand developedantibodies that cross-reacted with MSA( Fig. 1) . We observednodifference in antibodylevelsbetween the non-treated and the pravastatin-treated animals. Cholesterol levels were measured in the sera of all animals at the end of the experimental period.
No differenceswere observed between the control miceand the mice immunizedwith β 2 GP1orHSA.However,pravastatin treatment resultedina21% reduction in cholesterol levels both in the β 2 GP1-immunized and HSA-immunized mice ( Table 2) .
Quantification of atheroscleroticlesiondevelopment
The extent of atherosclerotic lesion development wasanalysed in the thoraco-abdominal aorta and in the aortic roots after 14 weeks of high-cholesterol diet. We observedthat lesion development wassimilarbetween β 2 GP1-immunized mice, HSA-immunizedmiceand non-immunizedcontrol mice, whereas pravastatin-treatment significantly reduced lesion development in the thoraco-abdominala orta for both β 2 GP1-immunized (p<0.05) and HSA-immunized groups (p<0.01) (Fig. 2A) .L ikewise for the roots, no difference wasobservedinlesion development between β 2 GP1-immunized mice, HSA-immunized mice and nonimmunized control mice. Pravastatin treatment reduced lesion sizeinthe mice immunizedwith either β 2 GP1orHSA.Differences,however,w ere notstatistically significant (p=0.08) (Fig.  2B) .
Quantitative immunohistochemical analysis of lesions in the aorticr oots
We analysed the lesionsinthe aortic roots by Masson'strichrome staining,w hich stains the collagena nd smoothm uscle cells composing the fibrous cap, whereas the lipid poola ppears as empty spaces in stained sections (Fig 3) . Aquantitative analysis of the results showednosignificant differences in the ratiobetween the fibrous capand lipidcore area betweenthe variousimmuni-zation and control groups (data not shown).Q uantitative immunohistochemical analysis for collagen, macrophages, SMC and CD4were made on aortic roots and normalized to the totallesion areas.The collagencontent wassignificantly lower in β 2 GP1-immunized mice than in theHSA-immunized or control mice. Pravastatin treatment hadn oe ffect on the collagen content (Fig. 4) .Inmicereceiving no pravastatin, we observeda 30% higher macrophage content in the plaquesofmiceimmunized with β 2 GP1o rw ith HSA thani nn on-immunizedm ice. Pravastatin treatment resultedi nas lightlyl ower macrophage content thatreached significanceonlyinHSA-immunized mice (Fig. 5A) . As ignificantly lowerSMC content waso bservedi n the β 2 GP1-immunized mice than in theHSA-immunized or the non-immunized control mice. Treatment of the β 2 GP1-immunized mice withpravastatin resulted in SMC contents thatwere comparable to the HSA-immunized mice(withorwithoutpravastatin) or non-immunized mice (Fig. 5B) . CD4 immunohistochemical analysis showedascattered staining. No significative differenceswere observed between the groups (Fig. 5C ). Macrophage staining was done using rabbit anti-mouse Mac 3 antibodies(Scale bar=500 µm), SMCstaining using rat anti-mousesm-MHC antibodies (Scalebar =500 µm), and CD4positivecells using ratanti-mouse CD4 antibodies (Scale bar =200 µm 
Gene expressionanalysis
The major complication of atherosclerosisisplaque rupture and the ensuing massive activation of the coagulation system, leading to thrombotic occlusions of arteries. To determine whether immunization with β 2 GP1orHSA (and statintreatment)has an effect on parameters knowntomodify plaque stability and coagulation-system activation, we measured mRNAlevelsofseveral cellt ype-specific proteins and inflammation-associated proteins in the thoraco-abdominal aorta. We measured mRNA levels of the followingcell-type marker proteins: CD68amacro-phage marker; CD4aT-lymphocyte marker; and CD25,the interleukin-2 receptor α -chain, am arker of activatedTcells. Expression of CD68 wass imilari nc ontrol mice and HSA-or β 2 GP1-immunized mice withoutpravastatin, whereas pravastatin treatment resultedinalower CD68 expression (Fig. 6A) .We observednodifference for CD4 (Fig. 6B) . Compared to control mice, CD25 expression was50-fold higher in β 2 GP1-immunized mice and 20-foldh igheri nH SA-immunized mice. Pravastatin treatment reduced CD25 expression by 50% in β 2 GP1-immunized mice (p =0.10) and had no effect in HSA-immunizedmice (Fig. 6C) .
mRNAl evelso fp roteinsk nown to modify plaque stability were alsomeasured: interferon-gamma(IFN-γ ), reduces plaque stability by decreasing collagensecretion by SMC and by contributing to SMC apoptosis; MMP-9, aprotease thatisknown to destabilize atherosclerotic plaques; TF,t he principal trigger of blood coagulation; MCP-1, the monocyte chemoattractant protein; iNOS, the inflammation inducible NO synthase; and IL10, the anti-inflammatorycytokine. We observedthat immunization with both β 2 GP1and HSA resulted in an increased expression in IFN-γ ,MMP-9, TF and MCP-1 and to alesserextent iNOS (Fig.  7) . Consistently, the increase in β 2 GP1-immunized mice wassignificantly higher (2-to 3-fold) than in HSA-immunizedm ice. Pravastatin treatment resultedinareduction in mRNAlevelsof most of the marker proteins in the β 2 GP1-immunized mice, but not in the HSA-immunizedm ice ( Fig. 7) . Expression of IL10 wasonlydetectable in the non-immunized group and in twomice in the β 2 GP1-immunized mice receiving pravastatin (not shown).I nterestingly, in these twom iceI FN-γ expression was very low.
Discussion
The presence of anti-β 2 GP1antibodies has beenassociatedwith accelerated atherosclerotic lesion development. In the present study,weinvestigated whether anti-β 2 GP1antibodies had an effect on the development and cellularc omposition of advanced atherosclerotic plaques. We observedt hat immunization of LDLR-deficient micewith human β 2 GP1, or HSAasanimmunization control, resultedi nt he formation of autoantibodies against murine β 2 GP1, or mousealbumin, respectively.After 14 weeks on ah igh-fatd iet, alla nimals had developeda dvanced lesions. No difference wasnoted in lesion size in the thoraco-abdominal aortas or aortic roots of mice immunizedw ith either β 2 GP1orHSA,compared to non-immunizedmice. Aprevious study hads hown that immunization of LDLR-deficient mice with β 2 GP1accelerated the formation of earlylesions in chowfed mice, buth ad,a si no ur study,n oe ffect on the sizeo ft he lesions in mice fedahigh-fatdiet (13) . Plaque size maynot be the most relevant clinicalp arameter.L ethal complications of atherosclerosis, suchasunstable angina and myocardialinfarction, areassociatedwith plaque rupture,which is more dependent on plaque composition than on plaque size (11) .For this reason our study focussed on measuring changes in plaque composition and analysis of plaque vulnerability-associatedinflammatorymarker proteins.
Analysis of thec omposition of lesions revealed ar educed SMC content and collageninthe β 2 G1-immunized mice, butnot in the HSA-immunizedmice. This mayberelated to higher expression in the aorta of β 2 GP1-immunized mice of IFN-γ (an inhibitoro fS MC proliferation and collagens ynthesis) and of MMP-9 (a collagendegrading proteinase) (11, 12) . As SMCand collagena ssurefibrous-cap stability,t heir loss is an important factor leading to plaque weakening and rupture (11) .I no ur analysis, immunization with β 2 GP1o rH SA increased macrophage content of the root sections,but had no effect on macrophage content of the thoraco-abdominal aorta. This difference might reflect as lowerp rogression of atherosclerotic lesions withinthe abdominal aorta (22) .Ananalysis of CD4 content of the plaquesdid not reveal anydifferences between control mice and β 2 GP1-or HSA-immunized mice.
An importantaspect of atherosclerosis, in addition to plaque composition, is the activation state of cellswithin the plaques.To analysethis, we measuredmRNAlevels of severalinflammationassociated proteins. Ourresultsrevealed that immunization with β 2 GP1orHSA resulted in markedlyhigher expression of CD25, amarkerofactivated Tcellsinthe atheroscleroticlesions.Moreover,wemeasuredincreased expression of inflammation-associated proteinssuchasIFN-γ ,MMP-9, TF,MCP-1 andiNOS.Increases were greater in the β 2 GP1-immunizedm ice than in the HSA-immunizedmice.Our data therefore suggest that the presence of autoantibodies, irrespective whether thesea re directed against β 2 GP1o ra lbumin,i samajor factorr esponsible for a morei nflammatory phenotype of advanced lesions.W ea lso measuredm RNAl evels of IL-10, an important anti-inflammatorycytokine.Itwas detectable in all control mice andundetectable in most of the immunized mice. Thesedata suggest that immunization with β 2 GP1and HSA reduces IL-10 expression.
Takent ogether,o ur data implyt hat immunization with β 2 GP1o rH SA increases the inflammatoryp henotype of atherosclerotic plaques. Thea lterationsa ppeart ob eg reater in β 2 GP1-immunized mice than in HSA-immunized animals.Our data do not allowustodetermine whether the phenotypic differences between β 2 GP1-and HSA-immunized mice are due to spe- Valuesare mean ±SEM. *p<0.05, **p<0.01, ***p<0.005. Thegroups of miceanalysed were:Control groupn=8, HSA-pravastatin n=5, HSA+pravastatinn= 6, β 2 GP1 -pravastatinn=5, β 2 GP1 +pravastatinn=4. cific anti-β 2 GP1-mediated effects,todifferent autoantibodylevelso rt oadifferent stoichiometryb etween antibodiesa nd antigen. Plasma concentrations of albumin aremuch higher than those of β 2 GP1and therefore even with similarantibody concentrations,the natureofimmune complexes is likelytobedifferent. The observation thatpravastatin treatment reduced the response to immunization with β 2 GP1but not with HSA suggests that immunization with β 2 GP1has an additionalpathogenic effect.One mechanism mayb es pecificallyr elated to β 2 GP1. Anti-β 2 GP1 antibodiesand aPLA areknown to activate endothelialcells and monocytes (9, 10, 23) . Therefore, these antibodies mayfacilitate the influx and activation of monocytesinto lesion areas. In addition, anti-β 2 GP1antibodies maycross-react with oxidized LDL, whichmay thenact as an additionalpathogenic factor (24) .Alternatively, immunization with β 2 GP1orHSA mayhaveled to the formation of circulating immune complexes with murine β 2 GP1o ra lbumin. Thep resence of such complexes induces a persistent inflammatorys tate thatm ay acceleratet he development of atherosclerotic lesionsa nd reduce plaque stability (25) .I na ddition, circulating immune complexesa ctivate complement, whichi sk nown to contribute to atherosclerosis (26) and also to the pathologicale ffectso fa PLA ( 27) . Finally, the processofimmunization itself,inparticularthe adjuvant used, mayc ontribute to atherosclerosis. Freund's completea djuvant accelerateda therosclerosisd evelopment in rabbits, whereas RIBI™, the adjuvant used in our present study,h ad no effect (28) .I nr abbits fed ac holesterol-richd iet, BCG immunization wasa ssociatedw ith increased surface expression of CD25 on peripheral lymphocytes, increased monocyte recruitment and enhanced atherosclerosis compared with non-immunized controls (29) . These studiesimplythat in atherosclerotic lesions, immune responses increase the expression of inflammatoryp roteins known to contribute to plaque weakening and rupture.
Statinsare knowntoreduce the risk of atherosclerotic complications (11, 17, 30) . This maybedue to areduction of cholesterol levels, butalso to pleiotropic anti-inflammatoryeffects. To establish whether treatment with statins reduces the severity of the phenotypic changes induced by immunization, we also included animals receiving pravastatin. We observed, as expected, thatstatin treatment reduced lesion development in both β 2 GP1-and HSA-immunized mice. Thiseffect wasmost pronounced in the thoraco-abdominal aorta, butalso evident in the aortic roots. Statin treatment hadlittle effect on collagenormacrophage content in the lesion areas.H owever,i n β 2 GP1-immunized mice, statint reatment increased SMC content and reduced the expression of CD68, CD25, and TF and several inflammation-associatedproteins. Theeffect of statins on plaque composition has beens tudiedb ys everal groups. In APOE*3-Leident ransgenic mice, atorvastatin hadnoeffect on the collagencontent of existing atherosclerotic plaques (31) . In contrast, we previouslyobservedathicker fibrous capand reducednumber of inflammatorycells in LDLR-deficient micereceiving ahigh-cholesterol diet and pravastatin in their drinking water (32) . The effect of statin treatment on metalloproteinase activity is well established. In cultured macrophages,M MP-9 synthesis and activity are decreased by fluvastatin (33) . In Watanabe heritablehyperlipemic rabbits,r eceiving pravastatin or fluvastatin, expression of MMP-1, MMP-3 and MMP-9 by macrophages in the atheroma waslower thaninacontrol group, whereas there wasnodifference in macrophage numbers (34).
Takent ogether,o ur resultss howt hat the presenceo fa ntibodies to β 2 GP1leads to an inflammatoryphenotype in atherosclerotic lesions, whichmay contribute to plaque weakening and ultimately plaque rupture.H owever,m ost of the effects do not appear to be specific for β 2 GP1, because immunizationw ith HSA ledtosimilar, albeitlesssevere, phenotypic changes.Immunization of LDLR-deficient micew ith β 2 GP1o ra lbumin maybeauseful approachtocreate in-vivo models to studymechanisms leading to plaque weakening.
